Liver Diseases  >>  peginterferon lambda-1a (BMS-914143)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
NCT01447394: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Withdrawn
3
0
US, Canada, Europe, RoW
Pegylated Interferon Lambda, BMS-914143, Pegylated Interferon Alfa-2a, Pegasys, Ribavirin, Ribasphere
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
03/14
08/14
PRINCIPAL, NCT01616524 / 2011-004885-14: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Completed
3
880
Japan, US, Europe, RoW
Pegylated interferon lambda (pegIFNλ), BMS-914143, Pegylated interferon alfa-2a (pegIFNα-2a), Pegasys, Ribavirin, Ribasphere, Daclatasvir, BMS-790052, Placebo matching Daclatasvir
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
06/14
09/14
NCT01754974 / 2012-003508-11: Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

Completed
3
40
Europe, RoW
Peginterferon Lambda-1a, BMS-914143, Ribavirin, Ribasphere, Peginterferon alfa-2a, Pegasys
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
09/14
09/14
NCT01718158 / 2011-005409-65: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Completed
3
444
Japan, US, Europe, RoW
Peginterferon Lambda-1a, BMS-914143, Peginterferon Alfa-2a, Pegasys®, Ribavirin, Copegus®, Daclatasvir, BMS-790052, Telaprevir, Incivek®
Bristol-Myers Squibb
Hepatitis C
10/14
10/14
DIMENSION, NCT01866930 / 2012-003280-22: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

Terminated
3
453
Europe, Canada, US, RoW
Pegylated Interferon Lambda-1a, BMS-914143, Daclatasvir (DCV), BMS-790052, Ribasphere (RBV)
Bristol-Myers Squibb
Chronic Hepatitis C Infection
08/15
08/15

Download Options